Topoisomerases relieve topological tension in DNA by breaking and rejoining DNA phosphodiester bonds. Type IB topoisomerases such as vaccinia topoisomerase (vTopo) and human topoisomerase I are structurally and mechanistically similar to the tyrosine recombinase family of enzymes, which includes bacteriophage lambda Integrase (Int). Previously, our laboratory identified peptide inhibitors of Int from a synthetic peptide combinatorial library. The most potent of these peptides also inhibit vTopo. Here, we used the same mixture-based screening procedure to identify peptide inhibitors directly against vTopo using a plasmid relaxation assay. The two most potent new peptides identified, WYCRCK and KCCRCK, inhibit plasmid relaxation, DNA cleavage and Holliday junction (HJ) resolution mediated by vTopo. The peptides tested bind double-stranded DNA at high concentrations but do not appear to displace the enzyme from its DNA substrate. WYCRCK binds specifically to HJ and perturbs the central base-pairing. This peptide also accumulates HJ intermediates when it inhibits Int-mediated recombination, whereas KCCRCK does not. Interestingly, WYCRCK shares four amino acids with a peptide identified against Int, WRWYCR. The octapeptide WRWYCRCK, containing amino acids from both hexapeptides, is more potent than either against vTopo. All peptides are less potent against the type IA Escherichia coli topoisomerase I or against restriction endonucleases. Like the Int-inhibitory peptide WRWYCR, WYCRCK binds to HJs, and both inhibit junction resolution by vTopo. Our results suggest that the newly identified WYCRCK and peptide WRWYCR interact with a distorted DNA intermediate arising during vTopo-mediated catalysis, or interfere with specific interactions between vTopo and DNA.
Introduction
Topoisomerases release topological tension during replication and transcription, and contribute to other essential processes, including chromosome segregation and DNA repair. 1 Type I topoisomerases cleave one strand of DNA at a time via a transesterification reaction involving an enzyme-DNA covalent complex. They are divided into two subfamilies, designated type IA and type IB. Type IA enzymes form 5′ phosphotyrosyl enzyme adducts. Type IB enzymes form 3′ phosphotyrosyl enzyme adducts. 1, 2 In both cases, the free DNA end rotates around the continuous strand, changing the linking number (and thus superhelical density) of the substrate. After rotation, the free hydroxyl group attacks the covalent enzyme-DNA linkage nucleophilically, regenerating an intact DNA strand and a non-covalently associated enzyme. Type IB topoisomerases relax either positive or negative supercoils and are stimulated by but do not require magnesium cations. 1, 2 Sequence and structural comparisons have shown that vTopo is the simplest of the type IB topoisomerases, consisting largely of the catalytic domain shared among members of the entire family. 3, 4 Although type IB topoisomerases had been thought to be restricted to eukaryotes and their viruses, genes encoding type IB topoisomerases have been found in Deinococcus and Pseudomonas, both with demonstrated enzymatic activity †. 5 Structural and mechanistic similarities extend to the catalytic domains of tyrosine recombinases, including those of phage lambda Integrase (Int) and the phage P1 Cre recombinase. 4, [6] [7] [8] [9] The type IB topoisomerases and tyrosine recombinases share four out of five active site residues necessary for catalysis. Both enzyme families cleave doublestranded DNA (dsDNA) as well as Holliday (fourway) junctions (HJ). [7] [8] [9] [10] [11] The related human topoisomerase I is the target of camptothecin and the related compounds irinotecan and topotecan, clinically important anti-cancer compounds. 12 The crystal structure of topotecan bound to hTopo-DNA complexes shows that the drug intercalates immediately downstream of the cleavage site and inhibits religation. 13 Camptothecin traps topoisomerase-DNA complexes, resulting in ternary complexes that block the transcription and replication machinery, 14 eventually leading to cell death. Camptothecin does not inhibit wild-type vTopo, although a point mutation confers some sensitivity. 15 Some DNA intercalators, such as nogalamycin, inhibit DNA cleavage by vTopo with an IC 50 of 0.7 μM, 16 but would be expected to be quite non-specific in their enzyme targets. Inhibitors of vTopo are expected to be effective against the topoisomerases of all pox viruses, including smallpox, a putative agent of bioterrorism, and may inhibit human topoisomerase I. Quite recently, very potent small molecules that inhibit vTopo specifically but not human topoisomerase I have been identified. 17 Topoisomerase inhibitors, including those specifically targeting the poxvirus enzymes, will be useful from both a mechanistic and a therapeutic perspective, since drug resistance will eventually arise against any inhibitor.
Previously, we identified hexapeptide inhibitors of lambda Int-mediated site-specific recombination by screening and deconvoluting synthetic peptide combinatorial libraries. 18, 19 These inhibitors have provided useful insights into the mechanism of Int site-specific recombination. [18] [19] [20] [21] [22] [23] One class of peptides identified against Int also inhibits DNA cleavage and plasmid relaxation mediated by vTopo, albeit at decreased potency with respect to Int. 20 To further analyze the similarities and differences between the type IB topoisomerases and the tyrosine recombinases, we have re-screened peptide libraries specifically for vTopo inhibitors using a plasmid relaxation assay. We have identified two relatively potent peptide inhibitors and have analyzed their mechanism of inhibition. These peptides inhibit DNA cleavage by vTopo of dsDNA and block the resolution of HJ substrates by vTopo without displacing the enzyme from duplex DNA containing its preferred cleavage/binding site. One of these newly identified peptides, WYCRCK, binds HJ specifically and perturbs bases near the crossover region within the vTopo cleavage site, thereby inhibiting DNA cleavage of this substrate. The inhibitors are more potent against enzymes with type IB mechanisms than Escherichia coli topoisomerase I (type IA) or restriction enzymes. The peptides may prove to be useful lead compounds for antipoxviral and/or anti-cancer drug development.
Results

Peptide inhibitors identified against vTopo
To identify amino acids of peptide inhibitors specific for vTopo, we performed a positional scanning screen of an L-amino acid synthetic peptide combinatorial library. 24 We used the procedure that was used earlier (outlined in (Figure 1(a) ) to find peptide inhibitors of phage lambda Int-mediated recombination. 18, 19 Briefly, mixtures of hexapeptides are added to plasmid relaxation assays containing vTopo and pUC19. During step 1, six different sets of peptide mixtures were screened, each set consisting of 20 mixtures representing all of the naturally occurring amino acid side-chains (represented by O, Figure 1 (a)) in one of the six positions in the peptide. The other five positions have an equimolar mixture of the 20 naturally occurring amino acids except cysteine (represented by X, Figure 1(a) ). Screening all 120 mixtures tests the contribution of all naturally occurring amino acid side-chains within a hexapeptide. To rank the contributions of each amino acid to the inhibitory potential, each mixture was tested at two concentrations (0.1 mg/ml and 0.2 mg/ml). An example of a plasmid relaxation assay testing the 20 peptide mixtures with the second position fixed is shown in Figure 1 (b). The amount of supercoiled substrate remaining was compared among the treated reactions (Figure 1(b) , lanes [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] and to untreated control reactions (Figure 1(b), lanes 1 and 2) . In the example shown, the mixtures containing amino acids C, F, L, M, W and Y at the second position inhibit vTopo activity most. These amino acids were included in the second screening step using dual defined mixtures, which contain two fixed amino acid positions (O) and four positions (X) with an equimolar mixture of one of the 19 amino acids, again lacking cysteine (Figure 1(a), step 2) . Instead of testing all of the 1200 possible combinations of 20 × 20 amino acids at each of three pairs of positions in the peptide, only the best amino acid candidates from the first step of the screen were included. The dual defined mixtures are less complex and thus the effective concentration of each constituent peptide was higher than in the single fixed position mixtures. 25 Each candidate mixture was tested at four concentrations (25 μg/ml, 6.3 μg/ml, 1.6 μg/ml and 0.4 μg/ml) to find the most potent inhibitory amino acid pairs. An example of a dose response assay testing the first and second position dual defined mixtures is shown in Figure 1 (c). For example, the peptide mixture with the fixed amino acids RC caused nearly complete inhibition of plasmid relaxation at 25 μg/ml (Figure 1(c) , lane 5). This mixture is more potent than the single position fixed peptide mixture with cysteine at the second position, also added at 25 μg/ml (Figure 1(c) , lane 5 versus lane 4). After the screening of 150 dual defined peptide mixtures, eight hexapeptides with defined sequences were synthesized (Figure 1(a) , step 3). The amino acids chosen for each fixed position of the eight peptides were: K or W at position 1, C or Y at position 2, C or L at position 3, R, Y, or I at position 4, C or E at position 5, and K or F at position 6. Of the specific peptides tested, the two most potent were KCCRCK and WYCRCK. WYCRCK shares amino acid identity with peptide In step 2, a subset of the 1200 peptide mixtures with two positions fixed are screened, which include fixed amino acids identified in step 1. These mixtures are less complex, 132,000 peptides per mixture, and their effective concentration is higher than the single fixed position peptide mixtures. In step 3, peptides with defined sequences are synthesized based on amino acids in the dual defined peptide mixtures that significantly inhibit enzyme activity. (b) Positional scanning of the peptide library against vTopo plasmid relaxation by peptide mixtures with second position fixed amino acids. Reactions contained 0.1 μg of pUC19, 0.2 mg/ml of each single fixed position peptide mixture, and were initiated with 0.25 pmol of vTopo and incubated at 30°C for 60 min. Lane 1, untreated supercoiled pUC19; lane 2, control reaction with only vTopo and pUC19; lanes 3-22, reaction products treated with the second position fixed peptide mixtures, each mixture tested is represented by the one-letter amino acid symbol shown above the gel image. R, relaxed plasmid DNA; S, supercoiled plasmid DNA. (c) Example of a dose response assay testing peptide mixtures with the first and second position fixed. The reaction conditions were the same as those used above. Lane 1, control with supercoiled plasmid pUC19; lane 2, vTopo and pUC19. For comparison, peptide mixtures with the second position fixed were tested in parallel with dual-defined peptide mixtures. Lanes 3 and 4 are reactions containing mixtures with the second position fixed as cysteine. Similarly, reactions separated in lanes 9 and 10 were treated with mixtures with the second position fixed as tyrosine. Lanes 5-8, dual defined peptide mixtures with arginine and cysteine at positions 1 and 2 of the peptides. Lanes 11-14, dual defined peptide mixtures with tryptophan and tyrosine residues at positions 3 and 4. S, supercoiled pUC19; vTopo, reaction with no added peptide.
WRWYCR, identified as a potent inhibitor of all Intmediated recombination in vitro. 19 To investigate the inhibitory contribution of the amino acids in both peptides, the octapeptide WRWYCRCK was synthesized and tested against vTopo in parallel with the hexapeptides.
Inhibition of vTopo-mediated plasmid DNA relaxation by the new peptide inhibitors
The inhibitory potency of the newly identified peptides was evaluated in DNA plasmid relaxation assays, using the conditions described by Klemm et al. 20 The IC 50 values of each inhibitor (Table 1) were determined by comparing the supercoiled substrate remaining versus the total amount of DNA in the mock-treated reaction, by densitometry and plotting as percentage inhibition versus peptide concentration. An example plasmid relaxation assay testing WYCRCK inhibition using two different plasmid substrates, pUC19 and pACYC184, is shown in Figure 2 (a) and (b). KCCRCK was twofold less potent than WYCRCK, indicating that the aromatic residues contribute to inhibitory activity. Since all the new peptides contain at least two cysteine residues, we tested the possibility that intermolecular or intramolecular disulfide bonds are important for inhibition. DTT added (final concentration 50 mM) to each peptide (12.5 μM) abolished their activity, suggesting that the inhibitory form is in fact a multimer (Figure 2 (a) and (b), lanes 9). To test directly the importance of the cysteine residues of WYCRCK, hexapeptides with alanine substituted for either cysteine residue were tested against vTopo-mediated pUC19 plasmid relaxation. WYARCK and WYCRAK (at concentrations up to 25 μM) do not appreciably block the relaxation of pUC19 by vTopo (Figure 2 (c), lanes 6 and 10 versus lane 2). WYARAK was tested but had no inhibitory activity (data not shown). Thus, each cysteine residue in WYCRCK is necessary but not sufficient for its maximal inhibitory activity.
The sequence specific DNA cleavage by vTopo allowed us to investigate whether the inhibitory potency of the peptides is related to the number of vTopo sites in the substrate, thereby addressing the specificity of inhibition. We compared the inhibition of vTopo relaxation activity of vTopo on equimolar pUC19 and pACYC184 plasmids. Although pACYC184 is ∼ 60% larger than pUC19, it has only eight vTopo cleavage sites compared to 14 present in pUC19. Thus, pACYC184 has a higher ratio of nonspecific to specific DNA. When peptide potency is normalized to the number of specific cleavages sites present in each plasmid, we observed a reduction in potency of 2.5-fold for WYCRCK and 2.0-fold for KCCRCK (for example, an IC 50 of 0.3 μM/site in pUC19 versus 0.8 μM/site in pACYC184 for WYCRCK) ( Table 1) . Although the analysis is complicated by possible variations in the context and/or accessibility of each cleavage site within each plasmid, the peptides lose potency in a manner correlated with the increase in non-specific DNA present in pACYC184 versus pUC19. Using the same analysis, WRWYCR showed a greater than fourfold decrease in potency against pACYC184 DNA relaxation mediated by vTopo compared to pUC19 (IC 50 of 0.5 μM/site in pUC19 versus 2.3 μM/site in pACYC184). WRWYCRCK, the most potent peptide tested in all in vitro assays, showed a 3.5-fold decrease in potency in relaxation assays using pACYC184, indicating that the longer peptide has greater non-specific inhibitory activity compared to WYCRCK (Table 1) . We presume that the extent of non-specific inhibitory activity of WYCRCK may be due to its DNA-binding properties seen in the vTopo binding assays below.
Peptides WYCRCK, KCCRCK and WRWYCRCK inhibit vTopo DNA cleavage
The vTopo catalytic reaction cycle consists of several steps: (1) non-covalent binding to duplex DNA; (2) strand cleavage; (3) strand passage; (4) a Inhibition of vTopo activity, unless specified otherwise. b The value before the slash (/) is the overall IC 50 for inhibiting relaxation of the plasmid; the value after the slash is the IC 50 calculated per vTopo site (i.e. 5.5 μM : 14 vTopo sites = 0.4 μM/site).
c DNA cleavage measured in the single turnover assay shown in Figure 3 . d Int recombination assays were performed in the presence of 100 ng of salmon sperm DNA, as described.
religation; and (5) dissociation of the enzyme from its substrate. 6 The inhibition of vTopo-mediated DNA cleavage was tested using a double-stranded suicide substrate, 26, 27 which contains the CCCTT vTopo recognition site six nucleotides upstream of the 3′ end of the scissile strand, as shown in Figure 3 . Upon transesterification by vTopo, the 6 nt section downstream of the cleavage site (denoted by arrow) diffuses away, trapping the vTopo-DNA covalent complex. 26 The covalent enzyme-DNA complex was separated from uncleaved DNA by SDS-PAGE. Peptide inhibition of DNA cleavage was tested using conditions that convert 40-50% of the substrate DNA into covalent enzyme-DNA complexes. The extent of cleavage was expressed as a percentage of covalent enzyme-DNA complex formed with peptide treatment normalized to an untreated reaction. Both WYCRCK and KCCRCK inhibited cleavage with an IC 50 of 0.5 μM. WRWYCRCK showed an IC 50 of 0.1 μM. The second parent peptide, WRWYCR, inhibited DNA cleavage with an IC 50 of 0.65 μM (Table 1) . We tested the inhibitory activity of wycrck, the all D-amino acid stereoisomer of WYCRCK, and found it was fourfold less potent in the single turnover cleavage assay than the L-stereoisomer. Presumably, this difference in potency reflects the asymmetric nature of the target. As for plasmid relaxation, 50 mM DTT abolished the activity of 5 μM peptide, although the cleavage activity of vTopo was unaffected by DTT (data not shown). Thus, the peptides inhibit vTopomediated cleavage of linear duplex DNA, and the oxidation state of the peptide is important for activity. The inhibitory activity of WYARCK and WYCRAK was compared to that of the parent peptide WYCRCK (Figure 3(b) ). The C>A peptides permitted almost 70% of DNA cleavage by vTopo ( Figure 3(b) ), while treatment with 5 μM WYCRCK permitted only 11% of vTopo DNA cleavage. As for inhibition of plasmid relaxation, both cysteine residues within WYCRCK are important for maximal inhibition of vTopo cleavage.
We explored the possibility that the peptides block vTopo activity by interacting with the enzyme directly. To test this effect, we reversed our previous order of addition of reaction constituents and incubated the inhibitory peptides with the enzyme first, then added the DNA substrate. In these conditions, WYCRCK and KCCRCK were found to be at least tenfold less active (data not shown); thus, interaction between vTopo and peptide is unlikely to be responsible for inhibition of catalytic activity.
Inhibitory peptides bind dsDNA but do not displace vTopo DNA binding assays using a 60 bp doublestranded substrate were performed to test if the inhibitory peptides prevent the non-covalent binding of vTopo to linear duplex DNA ( Figure  4 (a)). When vTopo is incubated with the substrate, approximately 20% of the bound DNA is in the form of covalent complexes, while 80% represents non-covalent vTopo-DNA complexes. 28 The same molar concentration of DNA substrate was added to the binding reactions as that used in the single turnover cleavage assays, and the minimal amount of vTopo necessary to produce a saturated band shift was determined (data not shown). An increasing amount of peptide was added to each reaction, including concentrations above and below the IC 50 concentration determined in single-turnover cleavage experiments. In Figure 4 (a), lane 8)). Formation of these aggregates was prevented in the presence of 50 mM DTT and vTopo-DNA complexes migrated into the gel, although they differed in appearance from the complexes made by vTopo alone binding to its substrate (e.g. Figure 4 (a), lane 9)), presumably because they contain some peptide. Peptide KCCRCK and particularly WRWYCRCK had greater non-specific dsDNA binding activity than WYCRCK or WRWYCR, evidenced by well-trapped complexes at lower concentrations of peptide ( Figure 4 . We conclude that the peptides bind dsDNA, and that binding is DTT-sensitive. The peptides may alter the conformation of the DNA, affecting its migration into the gel in the absence of vTopo, or they may simply bind in sufficient quantity to retard the substrate. The change in mobility is probably not due to a concerted bend, since ligation of short DNA fragments 29 did not occur more efficiently in the presence of peptides (data not shown) as it does when bound by a DNA bend-inducing protein. 30, 31 Inhibition of phage lambda Int-mediated recombination and accumulation of Holliday junction intermediates
As discussed above, peptides that inhibit Intmediated recombination by trapping proteinbound HJ complexes were isolated, 18, 19, 23 and some of these peptides, including WRWYCR, inhibited vTopo cleavage. 19 ,20 Therefore, we tested whether the peptides isolated as vTopo inhibitors can also inhibit Int-mediated recombination via the efficient bent-L recombination pathway, 32 which requires Int and integration host factor. Figure 5 (a) shows that WYCRCK causes accumulation of HJ intermediates with 0.8 μM treatment (20% of total DNA). In contrast, KCCRCK does not produce a significant amount of HJ intermediates at any concentration of peptide. Addition of WRWYCRCK resulted in a maximum accumulation of 50% of Holliday junction intermediates of the total input substrate at 0.1 μM (Figure 5(a) ), compared to 63% accumulation of junctions by WRWYCR at 0.1 μM (Figure 5(b) ). 19 The activity of the WRWYCRCK octapeptide could be due to the N-terminal WRWYCR part of its sequence. These data show that WYCRCK accumulates HJ intermediates during Int-mediated recombination, while KCCRCK does not. WYCRCK, WYARCK and WYCRAK were compared for their ability to trap HJ during bent-L Int-mediated recombination ( Figure 5(b) ). Treatment with 1.5 μM peptide produced 14% and 24% trapped HJ intermediates compared to WYCRCK, which accumulated 37% HJ intermediates. Both cysteine residues contribute to accumulation of HJ to some extent, but neither is as necessary for trapping HJ as it is for inhibiting dsDNA cleavage and plasmid relaxation by vTopo. When WRWYCR is added to recombination reactions, very high concentrations of peptide inhibit HJ accumulation because they inhibit even the first DNA cleavage stage of recombination, thereby blocking the progression of substrates through the pathway. [18] [19] [20] While WYCRCK does the same at high concentration, neither WYARCK or WYCRAK inhibit recombination completely at 500 μM. These results suggest that, similar to WRWYCR, peptide WYCRCK recognizes the central opening of HJ. This led us to test the interactions between the vTopo inhibitor WYCRCK and free HJ substrates.
WYCRCK and wycrck bind specifically to four-way DNA junctions Peptide WRWYCR accumulates HJ intermediates during Int-mediated recombination due to its high affinity for protein-free HJ (Table 1) . 34 Similarly, both WYCRCK and wycrck bind to synthetic HJ DNA, and form two distinguishable peptide-DNA complexes ( Figure 6 ). We determined the dissociation constants (K d ) for WYCRCK and wycrck by evaluating the amount of unbound HJ DNA in the presence of peptide (Figure 6(a) ); the concentration of peptide that left 50% unbound substrate HJ DNA was extrapolated to give affinity constants (K d ) of 35 nM and 25 nM for WYCRCK and wycrck, respectively (Figure 6(a) ). We also determined the specificity of peptide-binding to four-way junctions. Reactions were assembled using radiolabeled HJ and challenged with an excess of unlabeled HJ used in the vTopo resolution assays described below. The competitor HJs branch migrate over a 10 bp region, contain the preferred vTopo binding and cleavage sequence, and have greater four-way symmetry compared to the radiolabeled HJ showing the distinguishable shift. Addition of WYCRCK or wycrck (final concentration 100 nM) to the labeled junctions resulted in the formation of one predominant complex (Figure 6 lanes 16 and 32) . The greater competition of salmon sperm DNA with the junctions compared to the short dsDNA segment could be due to the greater sequence complexity present in salmon sperm DNA, which may have DNA that can extrude hairpins or stem-loop structures that could resemble HJ or three-way junctions. Overall, these data indicate that WYCRCK and wycrck bind to four-way junctions with greater affinity than to linear dsDNA, with wycrck having somewhat greater affinity and specificity for junctions. These results lead us to propose that the peptides recognize secondary structure or distorted DNA better than B-form DNA.
WYARCK and WYCRAK were less potent than WYCRCK at accumulating Int junctions. To relate this to their affinity for HJ, we titrated these substituted peptides on HJ using gel-shift assays. Each alanine-substituted peptide bound with two-to threefold less affinity than WYCRCK, as judged by the amount of free HJ DNA in lanes with 150 nM WYCRCK compared to 50 nM WYCRCK (Figure 6  (c), lanes 4 and 19 versus lanes 11 and 26) . The binding of both WYARCK and WYCRAK to HJ DNA was sensitive to DTT (Figure 6(c), lanes 15 and  30) . The C→A substituted peptides formed predominantly one complex (Figure 6(c) , lanes 7-14 and lanes 21-29) rather than the two complexes formed by WYCRCK (Figure 6(c) , lane 3 and 4, and 18 and 19) , showing a direct correlation between the number of cysteine residues present in each hexapeptide and the peptide-HJ complexes formed. Peptide WYARAK did not shift HJ substrates at all (data not shown).
Peptides block four-way junction resolution mediated by vaccinia topoisomerase HJ are intermediates found in both homologous recombination and site-specific recombination mediated by tyrosine recombinases. [7] [8] [9] 33 vTopo can resolve HJ into recombinant products if the junctions contain its preferred cleavage sites oriented head-to-head (Figure 7(a) ). 10, 11 Since WYCRCK and WRWYCR cause the accumulation of HJ during Int recombination with potencies in the nanomolar range and bind specifically to HJ DNA, we tested if the peptides inhibit HJ resolution by vTopo. HJ substrates for vTopo were constructed by annealing a [5′-
32 P]DNA oligonucleotide to three other oligonucleotides to form a partially mobile HJ in which branch migration could occur over the central 10 bp (Figure 7(a) ). 10 Concerted cleavage and religation by vTopo generates a labeled 59 bp linear duplex product. Equimolar amounts of junction substrate and vTopo were mixed as in the single-turnover DNA cleavage assays, and produced 30-40% 59 bp product when incubated for 10 min at 37°C (Figure 7(b) ). Addition of 2.5 μM WYCRCK or wycrck significantly inhibited the formation of the 59 bp recombinant product ( Figure  7 (b), lanes 13 and 31), while 2.5 μM KCCRCK completely inhibited HJ resolution (Figure 7(b) , lane 6). WRWYCRCK was the most potent inhibitor, completely inhibiting resolution at 0.63 μM ( Figure  7(b) lane 23) . The amount of resolved 59 bp product was quantified, expressed as the percentage of product, and normalized to the product in the absence of peptide, finally leading to the IC 50 value (Table 1) . To compare the potency of each peptide in inhibiting junction resolution to its potency at inhibiting single-turnover cleavage, the IC 50 values for peptide-treated reactions were normalized to the number of cleavage sites present in each substrate, which is two in the case of the HJ. This comparison shows that the peptides inhibit the resolution of HJ by vTopo with potencies very close to those observed in single-turnover DNA cleavage experiments.
To determine if KCCRCK and WYCRCK inhibit the cleavage of the HJ substrate or block the religation event by vTopo, the continuity of the radiolabeled DNA strand cleaved by vTopo was analyzed. vTopo-mediated junction resolution assays were performed in the presence and in the absence of peptide inhibitor, the reactions were quenched with SDS and treated with proteinase K, and then were separated on a DNA-denaturing gel. Processing of junctions by vTopo resulted in the 59 nt resolution product and a 26 nt cleaved product (Figure 7(c), lane 2) . The heterogeneity of the cleaved product is probably due to different numbers of amino acid residues remaining linked to it after treatment with proteinase K. Reactions in the presence of KCCRCK or WYCRCK resulted in a concomitant decrease in both the 26 nt cleaved product and the 59 nt religated product (Figure 7(c) , lanes 3-9 and 10-16, respectively). Thus, the peptides block the cleavage event that initiates strand exchange, resulting in reduced HJ resolution. The unligated products may be due to vTopo dissociating from some of the junctions before ligation. WYARCK and WYCRAK were also tested for their effects on vTopo-mediated junction resolution; in this case, 25 μM peptide resulted in 35% and 50% resolution inhibition, respectively (data not shown). Just as for Int-mediated bent-L recombination resolution, neither of these C→A peptides blocked vTopo junction resolution completely, even at concentrations far beyond their IC 50 .
WYCRCK perturbs the crossover point of four-way junctions WYCRCK inhibits HJ resolution by vTopo, accumulates HJ intermediates in lambda Intmediated recombination, and binds HJ. To test how WYCRCK influences HJ structure, KMnO 4 was used to probe the sensitivity of thymine bases near the junction crossover point when bound with WYCRCK in the presence and in the absence of competitor DNA. The synthetic HJ contained only one radiolabeled strand of 66 nt (Figure 8(a) ). The HJ was subjected to KMnO 4 in the presence and in the absence of WYCRCK at concentrations above and below the IC 50 values determined for DNA cleavage and HJ resolution by vTopo. The addition of 0.5 μM (final concentration) WYCRCK produced over a twofold increase in the sensitivity of the +2T compared to untreated four-way junctions, indicating that WYCRCK distorts the conformation of this base (Figure 8(c) ). The +1T is similarly affected by the presence of peptide, although to a lesser extent. The differential cleavage was quantified by densitometry and graphed as the relative amount of cleaved product in the presence of peptide compared to cleaved product in the absence of peptide. The addition of 50-fold molar excess of 60 bp competitor DNA over 32 P-radiolabeled HJ resulted in a small decrease in +2T sensitivity compared to the non-peptide-treated control (Figure 8(b), lanes 6-10 and (c) open  symbols) . These results show that WYCRCK perturbs thymine bases near the crossover region and alters the conformation of the bases within the vTopo cleavage site in the presence or in the absence of exogenous dsDNA.
Peptides inhibit a type IA topoisomerase I or restriction enzymes less than type IB topoisomerases
Type IA topoisomerases have a distinct structure and catalytic mechanism compared to type IB topoisomerases.
1,2 Both use a tyrosine nucleophile during transesterification reactions. Type IA topoisomerases form transient 5′ phosphotyrosyl intermediates, producing a free 3′ hydroxyl group, which then nucleophilically attacks the phosphotyrosyl bond, displacing the covalently bound enzyme and reforming a continuous DNA strand. In contrast, type IB topoisomerases form a transient 3′ phosphotyrosyl intermediate, producing a free 5′ hydroxyl group upon cleavage of DNA. Furthermore, type IA enzymes prefer binding to single stranded regions of DNA, while type IB enzymes require a dsDNA substrate. The peptides were tested against the E. coli type IA topoisomerase I, using reaction conditions similar to the vTopo plasmid relaxation assay (see Materials and Methods). These reactions were incubated for 15 min, the minimal amount of time necessary to achieve 80-90% relaxation of pUC19 ( Figure 9 ; and data not shown). Peptide WYCRCK did not inhibit plasmid relaxation by E. coli topo I substantially until reaching a concentration of 25 μM (Figure 9 , lane 2 versus lane 8, compare the amount of completely supercoiled DNA remaining in the reaction), whereas at this concentration, vTopomediated plasmid relaxation was blocked completely (Figure 2(a), lane 8) . WYCRCK and KCCRCK inhibited E. coli topo I with similar potencies, with an IC 50 of 21 μM and 24 μM, respectively. WRWYCRCK had a similar IC 50 of 5.5 μM against both vTopo and E. coli topoisomerase I in assays measuring the relaxation of pUC19. WYCRCK and KCCRCK are fourfold and twofold less potent against E coli topoisomerase I, respectively, than against vTopo (Table 1) .
To test the specificity of the peptides further, inhibition of cleavage by three different restriction enzymes (EcoRI, PstI and XbaI) was determined. Restriction enzymes cleave DNA by hydrolysis rather than by transesterification. The enzymes chosen each restrict at a single site within pUC19. Peptide inhibition assays were performed using buffer conditions and concentrations of pUC19 identical with those used in the plasmid relaxation assays. One unit of restriction enzyme was added to reactions followed by incubation at 37°C for the length of time that produced 50-80% digested product. The reactions were quenched by the addition of SDS and samples were analyzed by agarose gel electrophoresis. The amount of cleaved product in the presence of peptide was normalized to the amount of product in the absence of peptide, and expressed graphically as % inhibition with respect to peptide concentration. The IC 50 values for the peptides tested are shown in Table 1 
Discussion
Our laboratory previously identified peptide inhibitors against λ Int-mediated recombination by screening mixture-based combinatorial peptide libraries. 18, 19 Type IB topoisomerases, including human topoisomerase I and vTopo, are structurally and mechanistically related to Int. [1] [2] [3] [4] [7] [8] [9] Our most potent peptides isolated as Int inhibitors, WRWYCR and KWWCRW, also blocked DNA cleavage and plasmid relaxation by vTopo and human topoisomerase I. 19, 20 This was surprising, because the peptide inhibitors do not appear to interact directly with the Int active site, [18] [19] [20] 23 but stabilize the HJ recombination intermediate by interacting with branched DNA molecules (K. Kepple, N. Patel and A.S., unpublished results). 34, 35 We set out to identify and characterize the structure of inhibitors screened directly for inhibiting vTopo-mediated plasmid relaxation, and to determine how similar or different they are from the previously identified inhibitory peptides. The two most potent peptides identified by the screen described herein are WYCRCK and KCCRCK. Because WYCRCK shares amino acid identity with WRWYCR, we also characterized the octapeptide WRWYCRCK. The amino acid sequence shared between WYCRCK and WRWYCR suggests that the peptides inhibit Int and vTopo via a common mechanism. On the other hand, peptide KCCRCK with its three dispersed positive charges resembles the structure of polyamines, spermidine in particular. In fact, hexamine compounds that aggregate also inhibit DNA cleavage by human topoisomerase I. 36 The newly identified peptides inhibit vTopo plasmid relaxation with potency similar to that of the Int-inhibitors KWWCRW and WRWYCR. All these peptides bind duplex DNA and block vTopomediated DNA cleavage (the first transesterification step) without displacing vTopo from its substrate (Table 1; Figure 5 ). The KCCRCK peptide showed no significant difference in potency between inhibiting relaxation of pUC19 (14 vTopo sitesp, 192 bp of non-specific DNA per site) versus pACYC184 (8 vTopo sites, 530 bp of non-specific DNA per site), indicating that the number of vTopo sites in the substrate or the total number of basepairs in the substrate was irrelevant. We conclude that KCCRCK's affinity for dsDNA is the determining factor in its inhibition of vTopo and that an approximately twofold difference in DNA or sites does not affect its potency. The WYCRCK peptide was about twice as potent at inhibiting relaxation by vTopo when we calculated the IC 50 per single vTopo site, while its overall inhibition of relaxation in the two plasmids was roughly equal. The peptide is probably titrated among vTopo sites, or more likely, vTopo-DNA complexes. In the case of WRWYCR, relaxation of the longer plasmid is inhibited roughly half as well as the shorter plasmid when simply considering total nucleotides, and is about four times less potent when considering the 2.8-fold difference in the ratio of nonspecific DNA to vTopo recognition site. This suggests that WRWYCR is titrated more by nonspecific DNA than WYCRCK. However, WRWYCR has less dsDNA-binding activity than peptide WYCRCK (in fact, has the lowest non-specific dsDNA-binding activity of all the peptides in this study; Figure 5 ). Peptide WRWYCR may bind to vTopo-DNA complexes more weakly than WYCRCK. While WRWYCRCK appears to be the most specific for vTopo-DNA complexes when comparing relaxation of pUC19 and pACYC184, this probably reflects that it has the highest affinity for non-specific DNA.
We discovered that WYCRCK is more potent when inhibiting Int-mediated recombination (IC 50 0.085 μM) than vTopo-mediated plasmid relaxation (IC 50 5.5 μM or 0.4 μM/site) and concomitantly traps junction intermediates, despite the fact that our Int recombination assays include non-specific DNA. WYCRCK binds free HJs and is able to block their resolution by vTopo. Peptide WRWYCR inhibits junction resolution almost twice as well as peptide WYCRCK, although their affinities for junctions differ by only 30%. In contrast, KCCRCK inhibits Int recombination less potently (IC 50 0.3 μM) than the other peptides and does not trap junction intermediates appreciably. We did not measure the affinity of peptides KCCRCK or WRWYCRCK for junctions directly, but these peptides do not appear to distinguish between the different contexts of the vTopo recognition sequence ( Table 1 ). The com- parison between inhibition of vTopo single turnover cleavage and HJ resolution showed that WRWYCR, KCCRCK, and WRWYCRCK have almost the same IC 50 value when inhibiting these two vTopo activities, while WYCRCK inhibits cleavage of suicide substrates better than resolution of junctions. The different readouts we obtain from different assays suggest that the peptides differ in their affinity for and/or mode of binding to doublestranded oligonucleotide substrates, supercoiled plasmids, and four-way junctions.
The IC 50 values of peptides inhibiting vTopomediated plasmid relaxation or DNA cleavage either on a double-stranded oligonucleotide or an HJ are all within a factor of 4 of each other, and relatively close to the apparent affinity for dsDNA. In contrast, peptides WRWYCR and WYCRCK bind to HJ substrates and inhibit Int-mediated recombination significantly better, by a factor of at least 5 ( Table 1) . We conclude that the inhibition of vTopo most likely depends on the peptides' interaction with dsDNA. In contrast, the inhibition of Intmediated recombination depends on the ability of the peptides to bind to four-way junctions. Kinetic analysis of vTopo single-turnover DNA cleavage led to proposals that this step is partially rate-limiting during vTopo catalysis. 37, 38 Our demonstration that the peptides inhibit the DNA cleavage step independently supports this, because the rate-limiting step would be expected to be highly sensitive to inhibitors.
As an indicator of specificity, we compared how effectively the inhibitors blocked DNA recognition and cleavage by three restriction enzymes, and plasmid relaxation by the structurally and mechanistically unrelated type IA topoisomerase encoded by E. coli, EcTopo. Given that each of the restriction enzymes has a single recognition sequence in pUC19, while EcTopo acts at many more sites within pUC19, the difference in IC 50 concentrations suggests that WRWYCR inhibits EcTopo with more specificity than it does the restriction enzymes (Table  1) . Most likely, the basis of the inhibition of restriction enzymes by all the peptides is their nonspecific DNA-binding activity. WRWYCRCK appears to inhibit all of these enzymes at a lower concentration, and has characteristics combining those of WRWYCR and WYCRCK, as expected. W Y C R C K , K C C R C K , W RW Y C R , a n d WRWYCRCK all contain cysteine residues. DTT severely curtails all of their activities, suggesting strongly that monomer peptides assemble into at least dimers and, in some cases, into higher multimers via disulfide bonds. Binding of the WRWYCR to HJs and inhibition of Int recombination is reduced severely by DTT. 19, 34 Both cysteine residues within peptide WYCRCK are very important to its activity. WYARCK and WYCRAK did not inhibit vTopomediated plasmid relaxation, and both had greatly reduced inhibitory activity against vTopo-mediated DNA cleavage of suicide substrates. In addition, these peptides had reduced activity in blocking vTopo-mediated junction resolution. WYARCK and WYCRAK modestly accumulated HJ intermediates during Int recombination and partially inhibited HJ resolution by vTopo. These peptides probably do not completely block resolution of HJ processing enzymes due to their lower affinity for HJ. WYARAK does not inhibit vTopo in any assay (data not shown). WYARCK and WYCRAK are restricted to assembling dimers via a single disulfide bridge, whereas WYCRCK could potentially form greater-order multimers or networks. Alternatively, WYCRCK may form two intermolecular disulfide linkages between two hexapeptides, resulting in a small ring that is presumably more rigid than an unconstrained peptide dimer. HPLC traces of peptide WYCRCK compared to those of the single cysteine derivatives or of the cysteine-lacking peptide indicate one predominant conformation that is probably a peptide dimer, with only small amounts of larger molecular mass species, and do not support the presence of high molecular mass networks or aggregates (data not shown).
Modes of inhibition by WYCRCK and WRWYCR underline differences between type IB topoisomerases and tyrosine recombinases
The fact that both WYCRCK and WRWYCR exhibit specific binding to HJs suggests that a similar DNA intermediate is formed during vTopo catalysis, for example a transiently denatured duplex DNA resembling the branch point of an HJ. Kwon and colleagues showed that both noncovalent and covalent interactions of vTopo with DNA induce unstacking within the vTopo recognition site. 38 This vTopo-DNA structure may share some character of the branchpoint of an HJ. KMnO 4 footprinting experiments of HJ containing the vTopo 5′-(C/T)CCTT +1 cleavage site near the crossover point show that the +2T and, to a lesser extent, +1T is perturbed by WYCRCK. The +2T base is very important for DNA cleavage, its removal decreases the rate of cleavage 60-fold. 39 Furthermore, the addition of the covalent adduct +2R diastereomeric benzo [c] phenanthrene between the +2 and +1 basepairs abolishes DNA cleavage by disrupting interactions between vTopo and specific bases at the cleavage site. 40 The +1T base of the 5′-(C/T)CCTT +1 cleavage site is in equilibrium between stacked and unstacked conformations when bound by vTopo, independently of DNA cleavage. 28, 41 This observation is consistent with our proposal that WYCRCK inhibits cleavage during HJ resolution by perturbing the position of the +1T and +2T bases. Perturbation of the junction center has been shown also for peptide WRWYCR (or KWWCRW). 34 Our biochemical analyses of peptide-DNA interactions indicate that peptides most likely bind to DNA deformed by the binding of vTopo and induce further conformational changes in the DNA structure. The recent cocrystal structures of the variola topoisomerase with DNA in either covalent or non-covalent complexes do not show any topoisomerase-induced deformation in the double helix. 42 Unlike the case of the tyrosine recombinase tetramers, in which such deformations are seen even in non-covalent complexes, 8 type IB topoisomerases act as monomers and such DNA deformations may be too transient and unstable for capture in the crystals, since they would not be stabilized by protein-protein interfaces. An alternative possibility is that the peptides interfere with the network of hydrogen bonds that appear to determine specific interactions between the topoisomerase and the T/CCCTT site, which evidently is necessary for positioning of the Arg130 catalytic residue, and thus for efficient cleavage. 42 As the enzyme does not rely on specific interactions to bind dsDNA, the peptides may interfere with such interactions and still permit non-specific binding to DNA. We propose that the difference in the potency of peptide inhibition of different enzymes is related to their affinity for different DNA conformations, either pre-existing or induced by specific enzymes (K. Kepple, N. Patel and A. S. unpublished results). 34 Vaccinia virus has at least two potential targets of the peptides: the topoisomerase itself, which is necessary for normal levels of early transcription, 43 and the A22R protein, an HJ resolvase similar to the E. coli RuvC protein and involved in the maturation of unit-length viral genomes. 44, 45 Our peptides may inhibit poxvirus growth but those comprised of L amino acids are expected to be unstable due to degradation. Previously, we showed that the Damino acid stereoisomer of WRWYCR is almost as active at inhibiting recombination as the L-stereoisomer; 19 in the present study, both D-amino acid peptides wrwycr and wycrck are effective inhibitors of vTopo-mediated plasmid relaxation and HJ resolution, and bind to free junctions. These Dpeptides should be resistant to peptidases and, if effective at blocking poxvirus growth, may prove to be interesting leads for a new class of anti-poxvirus compounds.
Materials and Methods
Preparation of DNA substrates
Synthetic oligonucleotides were 5′ end-labeled with phage T4 polynucleotide kinase (New England Biolabs) with [γ-32 P]ATP (New England Nuclear). Linear duplex DNA substrates (shown in Results) were annealed by heating two complementary oligonucleotides to 95°C in the presence of 0.2 M NaCl followed by cooling slowly to room temperature. Double-stranded DNAs were gelpurified. Supercoiled plasmid DNA was isolated from E. coli DH5α using the midi-prep kit from Promega Inc. (Madison WI).
Preparation of HJ DNA used in HJ resolution assays was performed as described. 7 Preparation of the HJ used in gel retardation assays was as follows: one oligonucleotide was radiolabeled, then the kinase reaction was heated to 95°C in the presence of 0.2 M NaCl. The three remaining oligonucleotides were added to an equimolar concentration and all were annealed by slowly cooling to room temperature, followed by gel purification as described. 34 The sequences of the four oligonucleotides are: T TT TT TATA -CAAGCTTAACTCCC-3′,  5′-GGGAGTTAAGCTTGTATAAATGAGGTACTGTTAC-CAATTCTCCAAGTGACTACGG-3′,  5′-CCGTAGTCACTTGGAGAATTCCTAACAGTACCTCATT-TATACCTGCAGCCGACGC-3′,  5′ -GCGTCGGCTGCAGGTATAAAAAAGCAGGCTTCCGG-CCGTACCGCC-3′.
Proteins
Vaccinia virus topoisomerase was a generous gift from Dr Stewart Shuman, while E. coli topoisomerase I was a generous gift from Dr. Ken Marians. Phage lambda integrase and excisionase, and E. coli integration host factor were purified as described. 19 Restriction enzymes were obtained from New England Biolabs (Ipswich, MA).
Peptides and concentration determination
Peptides with defined amino acid sequences and 95% purity were purchased from Sigma-Genosys Corp. (Woodlands, TX); peptides were modified by C-terminal amidation. Peptide concentrations were determined by measuring absorbance at 280 nm and calculating the concentration using the extinction coefficients 5690 M − 1 cm − 1 for tryptophan, 1289 M − 1 cm − 1 for tyrosine, and 120 M − 1 cm − 1 for cysteine, as described. 46 For peptides that do not contain tryptophan or tyrosine, molar concentration corresponds to the dry weight of lyophilized peptide suspended in a known volume of 10% (v/v) DMSO. Mixture-based combinatorial peptide libraries were synthesized and provided by Torrey Pines Institute for Molecular Studies (La Jolla, CA).
Topoisomerase plasmid DNA relaxation assays
Screening of mixture-based combinatorial peptide libraries was performed essentially as described. 18 Peptide mixtures were screened using plasmid relaxation assays in the presence of 5 mM MgCl 2 . Reactions (10 μl) containing 50 mM Tris-HCl (pH 7.5), 0.1 μg of pUC19, 5 mM MgCl 2 were initiated by adding 0.25 pmol of vaccinia topoisomerase along with peptide mixtures at the concentrations indicated. The reactions were incubated for 1 h at 30°C, quenched with a mixture of 5% (w/v) SDS, 25% (v/v) glycerol, 0.025% (w/v) xylene cyanol, 0.025% (w/v) bromophenol blue and separated on 1% (w/v) agarose gels electrophoresed in TBE (90 mM Tris, 90 mM borate, 2.5 mM EDTA). Gels were stained with 0.5 μg/ml of ethidium bromide for 20 min, washed with water and visualized by UV light. To determine peptide potency at inhibiting vTopo-mediated plasmid relaxation, 20 μl reactions contained 50 mM Tris (pH 7.5), 5 mM MgCl 2 , 0.3 μg of supercoiled pUC19 and various concentrations of peptide as indicated. Peptide(s) were preincubated with the DNA premix before addition of 0.5 pmol of vTopo, and reactions were incubated at 37°C for 5 min. Reactions using pACYC184 as the DNA substrate were identical with the reactions containing pUC19, except 0.47 μg (equimolar concentration) of supercoiled plasmid was added to the reaction before incubation at 37°C for 1 min. The amount of supercoiled DNA left in each reaction was determined by densitometry using the ImageQuant program (GE Healthcare Corp.). Percentage relative relaxation was expressed as the percentage of supercoiled substrate present in peptide-treated reactions normalized to input of DNA (DNA-only control). IC 50 concentration values were extrapolated from graphs of percentage relative relaxation versus peptide concentration.
Peptide inhibition of E. coli topoisomerase I plasmid relaxation
Reactions (20 μl) containing 0.3 μg of pUC19, 50 mM Tris-HCl (pH 7.5) and 5 mM MgCl 2 were pre-incubated with peptide at 37°C for 5 min. E. coli topoisomerase I (0.5 pmol final concentration)) was added and reactions were incubated for 15 min at 37°C, then stopped with 5 μl of 5% SDS, 50% glycerol, 0.025% bromophenol blue, 0.025% xylene cyanol. Reaction products were separated on 1% agarose gels in TBE and stained with 0.5 μg/ml of ethidium bromide. The IC 50 values were calculated as described above and are shown in Table 1 .
Peptide inhibition of vTopo single-turnover cleavage
Single-turnover reactions were performed as described. 20 The 18-mer scissile strand was 5′-labeled with polynucleotide kinase and annealed to the 30-mer complementary strand ( Figure 6 ). Reactions (20 μl) contained 50 mM Tris-HCl (pH 7.5), 0.1 pmol of 18-mer/30-mer annealed DNA substrate. Reactions were pre-incubated with peptide at 37°C for 5 min, initiated by the addition of 0.25 pmol of vaccinia topoisomerase, and incubated at 37°C for 15 s. Reactions were quenched by the addition of glycerol, SDS, bromophenol blue, xylene cyanol, and separated using 10% polyacrylamide gels containing 0.1% SDS and 0.5×TBE. Percentage relative cleavage was determined as the amount of covalent protein DNA complex formed normalized to the amount of the complex formed in reactions without peptide.
Vaccinia topoisomerase DNA-binding assays
Reactions (20 μl) contained 50 mM Tris-HCl (pH 7.5), 0.1 pmol of 60 bp duplex DNA substrate (pre-incubated for 10 min at 37°C with the appropriate amount of peptide unless otherwise stated) and initiated by adding 0.25 pmol of vTopo followed by incubation at 37°C for 5 min. Samples were adjusted to 10% glycerol and separated by native 6% (acrylamide/bisacrylamide 29:1, w/w) polyacrylamide gel electrophoresis containing 0.25×TBE for 2 h at 4°C. Gels were dried and viewed using a Molecular Dynamics Storm instrument (GE Healthcare Corp.).
Peptide inhibition of Int-mediated recombination
Bent-L recombination reactions (10 μl) were assembled as described, 23 and contained 1 nM 32 P end-labeled attLtenP'1 179 bp fragment, 4 nM unlabeled attLtenP'1, 50 ng salmon sperm DNA, 5 mM spermidine, and 50 ng/ ml of BSA. Reactions were initiated by the addition of integration host factor and lambda integrase, and incubated at 37°C for 1 h. Reactions were quenched with 0.5% SDS, xylene cyanol. Recombinant products were separated on 5% polyacrylamide (acrylamide/bisacrylamide 29:1, w/w) Tris-tricine SDS gels at 100 mA constant current. Gels were dried and the amount of HJ DNA accumulated in each reaction was determined by densitometry and expressed as the percentage of total input DNA.
Peptide binding to Holliday junction DNA and competition assays
Reactions (20 μl) contained 50 mM Tris-HCl (pH 7.5), 5% glycerol, 5 mM NaCl, and 1 nM 32 P labeled synthetic HJ, which can branch-migrate over the central 7 bp and had arms of different lengths. 34 Reactions were initiated by the addition of peptide and were incubated for 20 min at 37°C. The amount and type of each competitor DNA is shown above the gel image ( Figure 6 ). Complexes were separated on 8% (acrylamide/bisacrylamide 29:1, w/w) polyacrylamide gels run for 10 h at 4°C; gels were dried and visualized on a Storm phosphorimager.
KMnO 4 footprinting of WYCRCK bound to Holliday junctions
The footprinting reactions of HJ bound to WYCRCK were done as described. 10 Reactions contained 50 mM Tris-HCl (7.5), 5 nM 32 P-radiolabeled HJ DNA and various concentrations of WYCRCK as shown ( Figure 6 ). Peptides were added to the DNA premix and allowed to bind at 37°C for 10 min. Peptide-HJ complexes were oxidized with 11 mM KMnO 4 , reduced with 2-mercaptoethanol and reactions were treated with piperidine at 90°C for 30 min. 34 Products were electrophoresed on 10% polyacrylamide (acrylamide/bisacrylamide 19:1, w/w) gels containing 7 M urea. Gels were dried and visualized by phosphorimaging (GE Molecular Dynamics Storm instrument). Cleaved thymine residues in or near the vTopo site were quantified using ImageQuant software and normalized to those not affected by peptide treatment in the same lane.
Inhibition of vTopo-mediated Holliday junction resolution
Reactions (20 μl) contained 50 mM Tris-HCl (pH 7.5), 0.1 pmol of synthetic HJ prepared as described, 10 and 0.5 pmol of vTopo. Reactions were incubated at 37°C for 10 min, quenched with SDS (added to 1% final concentration), digested with 1.0 μg of proteinase K, and extracted with phenol/chloroform. Samples were separated by native 5% polyacrylamide (acrylamide/bisacrylamide 19:1, w/w) gel electrophoresis and visualized using a Storm phosphorimager. To determine the strand continuity of the peptide inhibition of vTopo-mediated HJ resolution, reactions were also separated on 12% polyacrylamide (acrylamide/bisacrylamide 19:1, w/w) gels containing 7 M urea, 101 followed by exposure of the wet gel on a phosphorimager.
Peptide inhibition of restriction endonuclease cleavage
Reactions (20 μl) contained 0.3 μg of pUC19, 50 mM Tris-HCl (pH 7.5), 5 mM MgCl 2 , 1U of restriction enzyme, and were incubated at 37°C for a length of time that produced 60-90% digested plasmid. Reaction products were separated by electrophoresis on 1% agarose gels containing 90 mM Tris-HCl, 90 mM boric acid, 2.5 mM EDTA, and stained with 0.5 μg/ml of ethidium bromide. Densitometry measurements reflecting the cleaved product in the presence and in the absence of peptide were expressed as arbitrary densitometry units (a.u). A ratio was generated by dividing the a.u. corresponding to the cleaved product in the presence of peptide by the a.u. corresponding to the cleaved product without peptide treatment and substracted from 1 (1 -cleaved product with peptide/cleaved product without peptide) × 100, and designated % inhibition. The % inhibition was plotted with respect to peptide concentration and used to extrapolate the IC 50 values (Table 1) .
